Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 2/20 | 0.49 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.49 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.49 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.46 |
| ▸ | CHRNA7 | P36544 | 3/20 | 0.46 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.46 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.46 |
| ▸ | GBA1 | P04062 | 1/20 | 0.44 |
| ▸ | SPR | P35270 | 1/20 | 0.42 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17896405 | 0.92 | CHRM2 (0.49) | CHRM2CHRM1CHRM3HRH3CHRNA7 | |
| SCHEMBL12090436 | 0.83 | CHRM2 (0.64) | CHRM2CHRM1CHRM3HRH3CHRNA7 | |
| SCHEMBL12255642 | 0.83 | HRH3 (0.52) | CHRM2CHRM1CHRM3HRH3CHRNA7 | |
| SCHEMBL2603281 | 0.83 | CARM1 (0.55) | HRH3 | |
| SCHEMBL3978066 | 0.80 | CHRNB2 (0.50) | CHRM2CHRM1CHRM3HRH3CHRNA7 | |
| SCHEMBL22049077 | 0.79 | CHRM2 (0.72) | CHRM2CHRM1CHRM3HRH3CHRNB2 | |
| SCHEMBL21214526 | 0.78 | CHRM2 (0.44) | CHRM2CHRM1CHRM3HRH3CHRNA7 | |
| SCHEMBL2743291 | 0.77 | CHRM2 (0.68) | CHRM2CHRM1CHRM3HRH3CHRNA7 | |
| SCHEMBL9534698 | 0.76 | CHRNA7 (0.53) | CHRM2CHRM1CHRM3HRH3CHRNA7 | |
| SCHEMBL31054426 | 0.76 | CHRNA7 (0.53) | CHRM2CHRM1CHRM3HRH3CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8367679-B2 | Biaryl carboxamides | MERCK SHARP & DOHME CORP. (US) | 2013-02-05 | — | — | US | disclosed |
| US-8367679-B2 | Biaryl carboxamides | MERCK SHARP & DOHME CORP. (US) | 2013-02-05 | — | — | US | disclosed |
| US-20110230498-A1 | BIARYL CARBOXAMIDES | MERCK SHARP & DOHME CORP. | 2011-09-22 | — | — | US | disclosed |
| US-20110230498-A1 | BIARYL CARBOXAMIDES | MERCK SHARP & DOHME CORP. | 2011-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230498-A1 | BIARYL CARBOXAMIDES | PAFAH1B3, PAFAH1B2, FAAH2 | CHRM2 1680/4885CHRM1 1688/4885CHRM3 1048/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.